Reza Zonozi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reza Zonozi has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Anushya Jeyabalan
Division of Nephrology, Massachusetts General Hospital , Boston, MA
9 shared publicationsJohn L. Niles
Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA
7 shared publicationsKaren Laliberte
Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA
6 shared publicationsGabriel Sauvage
Division of Nephrology, Mass General Brigham Department of Medicine Boston, MA
4 shared publicationsJohn L Niles
Division of Nephrology, Massachusetts General Hospital , Boston, MA
3 shared publications- Orhan Efe
Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA
3 shared publications
Latest Publications
- 14 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 39 (7) , 1411-1419
Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia
Background: Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity, may be associated with a higher risk of thrombotic complications. Methods: We conducted a multicenter retrospective cohort study of individuals with membranous nephropathy and serum albumin <2.5 g/dL and evaluated risk factors for first thrombotic events. Results: Sixty-seven individuals met the inclusion criteria. Median serum creatinine was 1.2 mg/dL (Interquartile range [IQR] 0.9–1.6), median urine protein-to-creatinine ratio (UPCR) was 11.9 g/g (IQR 8.5–16.5), and median nadir serum albumin level was 1.9 g/dL (IQR 1.6–2.2). Twenty-four individuals (36%) received no thromboprophylaxis, 20 (30%) received prophylaxis with only antiplatelets, and 23 (34%) received anticoagulation prophylaxis. Thrombotic events occurred in 11 individuals (16%) with incidence rates of 0.11, 0.10, and 0.02 per person-year in the no prophylaxis, antiplatelet, and anticoagulation groups, respectively. In individuals with anti-PLA2R antibody-positive MN who did not receive anticoagulation thromboprophylaxis, higher anti-PLA2R antibody levels were associated with a higher risk of developing thrombotic complications (adjusted Hazard Ratio [HR] = 1.51 per 10 RU/mL increase in PLA2R, 95% Confidence Interval [CI]: 1.10–2.09, P = .012) after adjusting for serum albumin nadir and age. Conclusions: Higher anti-PLA2R antibody levels at the time of hypoalbuminemia are associated with a higher risk of thrombotic complications in individuals with anti-PLA2R-positive MN.
- 14 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 39 (7) , 1411-1419
Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia
Background: Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity, may be associated with a higher risk of thrombotic complications. Methods: We conducted a multicenter retrospective cohort study of individuals with membranous nephropathy and serum albumin <2.5 g/dL and evaluated risk factors for first thrombotic events. Results: Sixty-seven individuals met the inclusion criteria. Median serum creatinine was 1.2 mg/dL (Interquartile range [IQR] 0.9–1.6), median urine protein-to-creatinine ratio (UPCR) was 11.9 g/g (IQR 8.5–16.5), and median nadir serum albumin level was 1.9 g/dL (IQR 1.6–2.2). Twenty-four individuals (36%) received no thromboprophylaxis, 20 (30%) received prophylaxis with only antiplatelets, and 23 (34%) received anticoagulation prophylaxis. Thrombotic events occurred in 11 individuals (16%) with incidence rates of 0.11, 0.10, and 0.02 per person-year in the no prophylaxis, antiplatelet, and anticoagulation groups, respectively. In individuals with anti-PLA2R antibody-positive MN who did not receive anticoagulation thromboprophylaxis, higher anti-PLA2R antibody levels were associated with a higher risk of developing thrombotic complications (adjusted Hazard Ratio [HR] = 1.51 per 10 RU/mL increase in PLA2R, 95% Confidence Interval [CI]: 1.10–2.09, P = .012) after adjusting for serum albumin nadir and age. Conclusions: Higher anti-PLA2R antibody levels at the time of hypoalbuminemia are associated with a higher risk of thrombotic complications in individuals with anti-PLA2R-positive MN.
- Open Access
- 11 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6)
Long-term B-cell depletion with rituximab in relapsing, refractory and severe lupus nephritis: a retrospective case series
Background: B-cell depletion with anti-CD20 agents has been evaluated as part of induction immunosuppression (IS) in lupus nephritis (LN). Data on its long-term efficacy for maintenance of remission remains limited. Methods: Retrospective case series evaluating outcomes in patients with relapsing, refractory and severe LN at diagnosis who received rituximab (RTX)-induced continuous B-cell depletion for both induction and maintenance at Massachusetts General Hospital from 2008 to 2023. Results: A total of 26 patients with active LN were included. Eighty-eight percent (23/26) had class III/IV ± V on kidney biopsy; 12% (3/26) had pure class V LN. Median follow-up (from first to last RTX) was 32 months [interquartile range (IQR) 14–68]; median cumulative dose of RTX was 10 g (IQR 6–17). At RTX initiation, all patients received prednisone and oral IS with an intention to taper off oral agents in 12 months. Eighty-one percent (21/26) achieved at least partial remission. Median prednisone dose decreased from 30 to 5 mg/day at 6 months (P < .01). Fifty-eight percent (15/26) of patients at 12 months and 79% (11/14) at 24 months were on RTX monotherapy. Six renal relapses occurred in five patients with median time-to-first relapse of 43 months (range 24–142); all episodes but one were preceded by B-cell repopulation. Five patients developed end-stage kidney disease; all had creatinine >2 mg/dL at RTX initiation. Thirty-one percent (8/26) experienced severe infections requiring hospitalization. No deaths occurred. Conclusion: Long-term continuous B-cell depletion may be an effective treatment strategy in patients with LN who have failed prior IS or with severe disease at diagnosis. Future controlled studies are needed to further evaluate this approach as the backbone therapy in LN.
- 11 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6)
Open AccessLong-term B-cell depletion with rituximab in relapsing, refractory and severe lupus nephritis: a retrospective case series
Background: B-cell depletion with anti-CD20 agents has been evaluated as part of induction immunosuppression (IS) in lupus nephritis (LN). Data on its long-term efficacy for maintenance of remission remains limited. Methods: Retrospective case series evaluating outcomes in patients with relapsing, refractory and severe LN at diagnosis who received rituximab (RTX)-induced continuous B-cell depletion for both induction and maintenance at Massachusetts General Hospital from 2008 to 2023. Results: A total of 26 patients with active LN were included. Eighty-eight percent (23/26) had class III/IV ± V on kidney biopsy; 12% (3/26) had pure class V LN. Median follow-up (from first to last RTX) was 32 months [interquartile range (IQR) 14–68]; median cumulative dose of RTX was 10 g (IQR 6–17). At RTX initiation, all patients received prednisone and oral IS with an intention to taper off oral agents in 12 months. Eighty-one percent (21/26) achieved at least partial remission. Median prednisone dose decreased from 30 to 5 mg/day at 6 months (P < .01). Fifty-eight percent (15/26) of patients at 12 months and 79% (11/14) at 24 months were on RTX monotherapy. Six renal relapses occurred in five patients with median time-to-first relapse of 43 months (range 24–142); all episodes but one were preceded by B-cell repopulation. Five patients developed end-stage kidney disease; all had creatinine >2 mg/dL at RTX initiation. Thirty-one percent (8/26) experienced severe infections requiring hospitalization. No deaths occurred. Conclusion: Long-term continuous B-cell depletion may be an effective treatment strategy in patients with LN who have failed prior IS or with severe disease at diagnosis. Future controlled studies are needed to further evaluate this approach as the backbone therapy in LN.
- Open Access
- 30 November 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 944-947
Combination Induction Immunosuppression With Rituximab, Cyclophosphamide, and Prednisone for Fibrillary Glomerulonephritis
- 30 November 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 944-947
Open AccessCombination Induction Immunosuppression With Rituximab, Cyclophosphamide, and Prednisone for Fibrillary Glomerulonephritis
- 12 July 2024
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 31 (3) , 194-205
ANCA-Associated Vasculitis
- 12 July 2024
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 31 (3) , 194-205
ANCA-Associated Vasculitis
- Open Access
- 1 March 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (1) , 99-106
Nefropatia por oxalato e suplementação crônica de cúrcuma: relato de caso
RESUMO Relatamos o caso de um homem de 69 anos que se apresentou para exame de rotina e descobriu-se incidentalmente que ele tinha insuficiência renal, com histórico inicialmente não revelador e sedimento urinário brando. Ele foi diagnosticado com nefropatia por oxalato no contexto de suplementação crônica de cúrcuma e antibioticoterapia crônica com diarreia associada. Nosso caso fornece diversas sugestões importantes sobre nefropatia por oxalato. Primeiro, o diagnóstico requer elevado índice de suspeita clínica. A suspeita clínica é incomum, a menos que haja evidência óbvia no histórico, como bypass gástrico em Y de Roux ou envenenamento por etilenoglicol. O diagnóstico pode ser confirmado por achados histopatológicos e corroborado por níveis séricos de oxalato e excreção urinária de 24 horas. Segundo, o diagnóstico pode passar despercebido pelo patologista devido às características dos cristais, a menos que o patologista renal estabeleça como regra examinar rotineiramente todas as seções coradas com H&E sob luz polarizada. Isso deve ser feito com H&E, pois, outras colorações dissolvem os cristais. Em terceiro lugar, um cristal de oxalato em biópsia por agulha de rotina é considerado patológico, contribuindo potencialmente para LRA ou para DRC de maneira significativa. Em quarto lugar, a oxalose secundária pode ser amplamente mitigada ou prevenida em muitos casos, especialmente casos iatrogênicos. Isso pode ser feito pelo cirurgião ou pelo gastroenterologista, fornecendo instruções adequadas aos pacientes sobre uma dieta restrita em oxalato ou outras medidas dietéticas específicas. Por fim, esse caso destaca o sucesso que resulta da cooperação e comunicação entre o patologista e o médico assistente.
- 1 March 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (1) , 99-106
Open AccessNefropatia por oxalato e suplementação crônica de cúrcuma: relato de caso
RESUMO Relatamos o caso de um homem de 69 anos que se apresentou para exame de rotina e descobriu-se incidentalmente que ele tinha insuficiência renal, com histórico inicialmente não revelador e sedimento urinário brando. Ele foi diagnosticado com nefropatia por oxalato no contexto de suplementação crônica de cúrcuma e antibioticoterapia crônica com diarreia associada. Nosso caso fornece diversas sugestões importantes sobre nefropatia por oxalato. Primeiro, o diagnóstico requer elevado índice de suspeita clínica. A suspeita clínica é incomum, a menos que haja evidência óbvia no histórico, como bypass gástrico em Y de Roux ou envenenamento por etilenoglicol. O diagnóstico pode ser confirmado por achados histopatológicos e corroborado por níveis séricos de oxalato e excreção urinária de 24 horas. Segundo, o diagnóstico pode passar despercebido pelo patologista devido às características dos cristais, a menos que o patologista renal estabeleça como regra examinar rotineiramente todas as seções coradas com H&E sob luz polarizada. Isso deve ser feito com H&E, pois, outras colorações dissolvem os cristais. Em terceiro lugar, um cristal de oxalato em biópsia por agulha de rotina é considerado patológico, contribuindo potencialmente para LRA ou para DRC de maneira significativa. Em quarto lugar, a oxalose secundária pode ser amplamente mitigada ou prevenida em muitos casos, especialmente casos iatrogênicos. Isso pode ser feito pelo cirurgião ou pelo gastroenterologista, fornecendo instruções adequadas aos pacientes sobre uma dieta restrita em oxalato ou outras medidas dietéticas específicas. Por fim, esse caso destaca o sucesso que resulta da cooperação e comunicação entre o patologista e o médico assistente.
- Open Access
- 1 March 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (1) , 99-106
Oxalate nephropathy and chronic turmeric supplementation: a case report
We present a case of a 69-year-old man who presented for routine check-up and was incidentally found to have kidney failure with an initially unrevealing history and bland urinary sediment. He was diagnosed with oxalate nephropathy in the setting of chronic turmeric supplementation and chronic antibiotic therapy with associated diarrhea. Our case provides several key insights into oxalate nephropathy. First, the diagnosis requires a high index of clinical suspicion. It is uncommonly suspected clinically unless there is an obvious clue in the history such as Roux-en-Y gastric bypass or ethylene glycol poisoning. Diagnosis can be confirmed by histopathologic findings and corroborated by serum levels of oxalate and 24-hour urinary excretion. Second, the diagnosis can often be missed by the pathologist because of the characteristics of the crystals unless the renal pathologist has made it a rule to examine routinely all H&E sections under polarized light. This must be done on H&E, as the other stains dissolve the crystals. Third, one oxalate crystal in a routine needle biopsy is considered pathologic and potentially contributing to the AKI or to the CKD in an important way. Fourth, secondary oxalosis can be largely mitigated or prevented in many cases, especially iatrogenic cases. This can come through the surgeon or the gastroenterologist providing proper instructions to patients on an oxalate-restricted diet or other specific dietary measures. Lastly, this case highlights the success that results from cooperation and communication between the pathologist and the treating physician.
- 1 March 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (1) , 99-106
Open AccessOxalate nephropathy and chronic turmeric supplementation: a case report
We present a case of a 69-year-old man who presented for routine check-up and was incidentally found to have kidney failure with an initially unrevealing history and bland urinary sediment. He was diagnosed with oxalate nephropathy in the setting of chronic turmeric supplementation and chronic antibiotic therapy with associated diarrhea. Our case provides several key insights into oxalate nephropathy. First, the diagnosis requires a high index of clinical suspicion. It is uncommonly suspected clinically unless there is an obvious clue in the history such as Roux-en-Y gastric bypass or ethylene glycol poisoning. Diagnosis can be confirmed by histopathologic findings and corroborated by serum levels of oxalate and 24-hour urinary excretion. Second, the diagnosis can often be missed by the pathologist because of the characteristics of the crystals unless the renal pathologist has made it a rule to examine routinely all H&E sections under polarized light. This must be done on H&E, as the other stains dissolve the crystals. Third, one oxalate crystal in a routine needle biopsy is considered pathologic and potentially contributing to the AKI or to the CKD in an important way. Fourth, secondary oxalosis can be largely mitigated or prevented in many cases, especially iatrogenic cases. This can come through the surgeon or the gastroenterologist providing proper instructions to patients on an oxalate-restricted diet or other specific dietary measures. Lastly, this case highlights the success that results from cooperation and communication between the pathologist and the treating physician.
- 11 December 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (3) , 351-359
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial
Objective To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. Methods We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level. Evaluations were conducted every 3 months. The primary endpoint was clinical relapse, defined as a modified BVAS/WG >0 by 36 months. Secondary endpoints included serious adverse events (SAEs) and rituximab exposure. Results 115 patients were enrolled. Median follow-up time was 4.1 years (IQR 2.5–5.0). By Kaplan-Meier analysis, 4.1% (95% CI 1.0 to 15.6) of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA arm, at 3 years after study entry (log-rank p=0.045). Total SAEs, including infectious SAEs, and deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049). In the B cell arm, patients received a mean of 3.6 (SD 2.4) infusions (3.6 g) per person over the median study follow-up time of 4.1 years, compared with 0.5 (SD 1.4) infusions (0.5 g) per patient in the ANCA arm (pConclusions Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy. Trial registration number NCT02749292.
- 11 December 2023
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 83 (3) , 351-359
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial
Objective To compare two long-term remission maintenance strategies for antineutrophil cytoplasmic antibody (ANCA) vasculitis. Methods We conducted a prospective, single-centre, open-label, randomised controlled trial of patients with ANCA vasculitis in remission after completing at least 2 years of fixed-schedule rituximab. In the B cell arm, rituximab was reinfused upon B cell repopulation; in the ANCA arm, rituximab was reinfused upon significant rise in ANCA level. Evaluations were conducted every 3 months. The primary endpoint was clinical relapse, defined as a modified BVAS/WG >0 by 36 months. Secondary endpoints included serious adverse events (SAEs) and rituximab exposure. Results 115 patients were enrolled. Median follow-up time was 4.1 years (IQR 2.5–5.0). By Kaplan-Meier analysis, 4.1% (95% CI 1.0 to 15.6) of patients had a clinical relapse in the B cell arm, compared with 20.5% (95% CI 11.9 to 34.1) in the ANCA arm, at 3 years after study entry (log-rank p=0.045). Total SAEs, including infectious SAEs, and deaths did not differ. The number of SAEs due to COVID-19 was higher in the B cell arm (p=0.049). In the B cell arm, patients received a mean of 3.6 (SD 2.4) infusions (3.6 g) per person over the median study follow-up time of 4.1 years, compared with 0.5 (SD 1.4) infusions (0.5 g) per patient in the ANCA arm (pConclusions Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy. Trial registration number NCT02749292.
- 29 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (724) , eadh4529
T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe disease and mortality from coronavirus disease 2019 (COVID-19), but the immune responses and clinical outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have yet to be fully defined. Here, we evaluate the cellular immune responses after both SARS-CoV-2 infection and vaccination in patients receiving the anti-CD20 therapy rituximab (RTX) and those with low B cell counts due to common variable immune deficiency (CVID) disease. Assessment of effector and memory CD4 + and CD8 + T cell responses to SARS-CoV-2 revealed elevated reactivity and proliferative capacity after both infection and vaccination in B cell–deficient individuals, particularly within the CD8 + T cell compartment, in comparison with healthy controls. Evaluation of clinical outcomes demonstrates that vaccination of RTX-treated individuals was associated with about 4.8-fold reduced odds of moderate or severe COVID-19 in the absence of vaccine-induced antibodies. Analysis of T cell differentiation demonstrates that RTX administration increases the relative frequency of naïve CD8 + T cells, potentially by depletion of CD8 + CD20 dim T cells, which are primarily of an effector memory or terminal effector memory (TEMRA) phenotype. However, this also leads to a reduction in preexisting antiviral T cell immunity. Collectively, these data indicate that individuals with B cell deficiencies have enhanced T cell immunity after both SARS-CoV-2 infection and vaccination that potentially accounts for reduced hospitalization and severe disease from subsequent SARS-CoV-2 infection.
- 29 November 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (724) , eadh4529
T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19
Individuals with primary and pharmacologic B cell deficiencies have high rates of severe disease and mortality from coronavirus disease 2019 (COVID-19), but the immune responses and clinical outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination have yet to be fully defined. Here, we evaluate the cellular immune responses after both SARS-CoV-2 infection and vaccination in patients receiving the anti-CD20 therapy rituximab (RTX) and those with low B cell counts due to common variable immune deficiency (CVID) disease. Assessment of effector and memory CD4 + and CD8 + T cell responses to SARS-CoV-2 revealed elevated reactivity and proliferative capacity after both infection and vaccination in B cell–deficient individuals, particularly within the CD8 + T cell compartment, in comparison with healthy controls. Evaluation of clinical outcomes demonstrates that vaccination of RTX-treated individuals was associated with about 4.8-fold reduced odds of moderate or severe COVID-19 in the absence of vaccine-induced antibodies. Analysis of T cell differentiation demonstrates that RTX administration increases the relative frequency of naïve CD8 + T cells, potentially by depletion of CD8 + CD20 dim T cells, which are primarily of an effector memory or terminal effector memory (TEMRA) phenotype. However, this also leads to a reduction in preexisting antiviral T cell immunity. Collectively, these data indicate that individuals with B cell deficiencies have enhanced T cell immunity after both SARS-CoV-2 infection and vaccination that potentially accounts for reduced hospitalization and severe disease from subsequent SARS-CoV-2 infection.
- Open Access
- 23 October 2023
- Published by Springer Nature in Research Square
Bronchitis during long-term treatment with rituximab for ANCA-associated vasculitis: a retrospective cohort study
Background Pulmonary complications from B cell depletion with rituximab remain with limited description in the literature. Our objective is to describe the frequency and risk factors for development of bronchitis in patients receiving prolonged rituximab. Methods We conducted a single-center retrospective cohort study of 113 consecutive adult patients with ANCA-associated vasculitis (AAV) who had continuous B cell depletion with rituximab for greater than 24 months. The primary outcome was an episode of cough measured with an ordinal scale as follows: 0 = no cough; 1 = daily cough, non-productive; 2 = cough with sputum production once daily; 3 = cough with sputum production twice or more daily. Secondary outcome measures included serum immunoglobulin G (IgG) level, sputum culture, and antibiotic use. Logistic regression analysis was used to assess the odds ratio of developing cough with smoking status, nadir IgG level, length of time on continuous B cell depletion, and lung involvement of AAV as independent variables. Results The median (IQR) follow-up (i.e., duration of continuous B cell depletion) was 3.4 years (IQR, 2.7–5.2). Five patients (4.5%) and 43 patients (38.4%) were current and former smokers, respectively. A non-productive cough was identified in 4.2% of patients (n = 5). Throughout follow-up, a daily cough with sputum production once daily was identified in 6.2% of patients (n = 7), and a daily cough with sputum production twice or more daily was identified in 11.5% of patients (n = 13). A specimen for sputum culture was obtained in 25 patients, 12 (48%) of which were positive for a bacterial organism. The most common was Haemophilus influenzae (n = 2). Antibiotics for suspected bacterial bronchitis were used in 19.5% of patients (n = 22). The median (IQR) nadir IgG level was 675 mg/dL (521–798). No patient received intravenous IgG supplementation. In univariate and multivariate logistic regression models, the smoking status, nadir IgG level, length of time on continuous B cell depletion, and lung involvement of AAV were not associated with an increased odds of developing a cough. Conclusions Bronchitis was seen in approximately one-fifth of patients with AAV on prolonged B cell depletion with rituximab.
- 23 October 2023
- Published by Springer Nature in Research Square
Open AccessBronchitis during long-term treatment with rituximab for ANCA-associated vasculitis: a retrospective cohort study
Background Pulmonary complications from B cell depletion with rituximab remain with limited description in the literature. Our objective is to describe the frequency and risk factors for development of bronchitis in patients receiving prolonged rituximab. Methods We conducted a single-center retrospective cohort study of 113 consecutive adult patients with ANCA-associated vasculitis (AAV) who had continuous B cell depletion with rituximab for greater than 24 months. The primary outcome was an episode of cough measured with an ordinal scale as follows: 0 = no cough; 1 = daily cough, non-productive; 2 = cough with sputum production once daily; 3 = cough with sputum production twice or more daily. Secondary outcome measures included serum immunoglobulin G (IgG) level, sputum culture, and antibiotic use. Logistic regression analysis was used to assess the odds ratio of developing cough with smoking status, nadir IgG level, length of time on continuous B cell depletion, and lung involvement of AAV as independent variables. Results The median (IQR) follow-up (i.e., duration of continuous B cell depletion) was 3.4 years (IQR, 2.7–5.2). Five patients (4.5%) and 43 patients (38.4%) were current and former smokers, respectively. A non-productive cough was identified in 4.2% of patients (n = 5). Throughout follow-up, a daily cough with sputum production once daily was identified in 6.2% of patients (n = 7), and a daily cough with sputum production twice or more daily was identified in 11.5% of patients (n = 13). A specimen for sputum culture was obtained in 25 patients, 12 (48%) of which were positive for a bacterial organism. The most common was Haemophilus influenzae (n = 2). Antibiotics for suspected bacterial bronchitis were used in 19.5% of patients (n = 22). The median (IQR) nadir IgG level was 675 mg/dL (521–798). No patient received intravenous IgG supplementation. In univariate and multivariate logistic regression models, the smoking status, nadir IgG level, length of time on continuous B cell depletion, and lung involvement of AAV were not associated with an increased odds of developing a cough. Conclusions Bronchitis was seen in approximately one-fifth of patients with AAV on prolonged B cell depletion with rituximab.